ArticleMedical oncology (Northwood, London, England)2025
Diosgenin enhances the effect of radiation on head and neck cancer cells through apoptosis induction, G2/M cell cycle arrest, and ROS generation.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a cornerstone in treating head and neck cancers, yet its effectiveness is often limited by factors such as hypoxia and cancer stem cells. This study evaluated the radiosensitizing potential of diosgenin in KB cancer cells and normal HDF cells exposed to 4 Gy X-rays, with or without diosgenin. Cell viability, apoptosis, cell cycle distribution, ROS production, and expression of intrinsic apoptosis-related genes were assessed using MTT assays, flow cytometry, and RT-qPCR, respectively. Diosgenin alone reduced KB cell viability and, when combined with radiation (63 μM + 4 Gy), further decreased viability to 27.93 ± 1.8%, which was significantly lower than with either treatment alone (p < 0.05), while exhibiting lower toxicity in HDF cells. Diosgenin also induced G2/M arrest and amplified radiation-induced apoptosis, sub-G1 accumulation, and ROS production. These effects correlated with a marked increase in the Bax/Bcl-2 mRNA ratio in the combination group compared to either treatment alone (p < 0.0001), indicating activation of the intrinsic apoptotic pathway. Overall, the results suggest that diosgenin enhances the effect of radiation on head and neck cancer cells and may serve as a promising adjunct to radiotherapy.
Indexed as
Identifiers
40900377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.